LONDON - BOSTON, 04 January 2024 (GLOBE NEWSWIRE) - SV Health Investors, a leading transatlantic venture capital and growth equity firm, is pleased to announce that it is bolstering its senior biotech team with the appointments of Nikola Trbovic as Managing Partner and of Jamil Beg as Partner. They will work alongside Kate Bingham, SV Managing Partner and Mike Ross, SV Senior Partner.
Jamil and Nikola take on leading roles in the diverse and experienced SV biotech investment team investing out of two core biotech funds: SV7 Impact Medicine Fund and SV Biotech Crossover Opportunities Fund.
Nikola Trbovic is promoted to the role of Managing Partner having joined SV Health Investors as a Partner in the biotech team in 2022. He was previously at Pfizer Ventures where he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities. Since joining SV, Nikola has been involved in transactions including leading the successful investment in Nimbus Therapeutics. Takeda agreed to acquire Nimbus in December 2022 for $4bn upfront and a potential further $2bn in milestone payments, seven months after SV’s initial investment in the company.
Nikola currently serves as a Director on the Boards of innovative biotech companies, Artios, Catamaran Bio, Prilenia, Sitryx and TrexBio.
Jamil Beg joins SV having previously worked at 5AM Ventures, a US-based life sciences venture fund, where he was Partner. He joins with a successful VC track record, and operational expertise. At 5AM he was responsible for investing in biotech companies across therapeutic areas and modalities and ranging from company creation to clinical-stage companies. Over his career, Jamil has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics, Nido Biosciences, RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), Transave Inhalation Therapeutics (merged with Insmed) and several stealth biotech startups.
Kate Bingham, SV Managing Partner commented: “These are exciting times for SV, with Nikola’s promotion and Jamil joining the biotech leadership team to support the growth of our platform as we build on SV’s 30-year track record of creating and investing in successful companies. During the past three decades these have delivered 24 new therapeutic drugs, of which six represent new drug classes, opening up a plethora of treatment options for patients. Nikola is an integral member of the SV team and has made significant contributions to the firm since he joined. Having served on boards with him prior to his joining SV, Mike and I knew Nikola would represent a good fit at SV. His scientific rigour and hands-on approach to supporting portfolio companies has helped ensure his success at SV to date. Jamil’s skill set will bring significant additional expertise to the team. We are excited to have him join our platform.”
Mike Ross, SV Senior Partner added: “It is fantastic to have Jamil join the senior biotech team, particularly given the significant overlap between his background and our biotech investment strategy. Jamil brings with him a successful track record of creating and building companies as well as making later stage investments. His deep operational expertise will be hugely valuable to our portfolio companies.”
Nikola Trbovic, who starts in his new role as Managing Partner, said: “I am excited to take on this role and contribute to the ongoing success of SV’s biotech platform, as well as SV as a whole. I was thrilled to join SV as a well-respected firm with such a long-standing record of investing in innovative companies developing ground-breaking therapeutics for patients. Having Jamil join the team will help continue to propel the biotech platform from strength to strength.”
The SV biotech team is supported by an extensive cohort of Venture Partners who are exclusive to SV and have deep drug discovery and development expertise spanning the full lifecycle of development.
About SV Health Investors
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV family of funds which includes funds dedicated specifically to biotech and dementia, invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With approximately $2.4 billion in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in, created and built more than 200 companies attracting global talent, entrepreneurs and pharma partners. To date, these investments have resulted in the licensing of 24 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients. For more information, please see www.svhealthinvestors.com.
